logo
Alcohol-related cancer deaths have doubled in recent years in the US

Alcohol-related cancer deaths have doubled in recent years in the US

Yahoo23-05-2025

The number of annual alcohol deaths due to cancer has doubled in recent years in the U.S., researchers said this week.
The tally rose from 11,896 in 1990 to 23,207 by 2021, according to data that was presented at the American Society of Clinical Oncology 2025 conference.
'Alcohol-associated cancer mortality has significantly increased in the U.S. over the past three decades, with a disproportionate burden observed in males and individuals aged 55 and older,' they wrote.
They reached these conclusions using data from the Global Burden of Disease database, which provides incidence and mortality estimates for 35 cancer types. They found that the rates increased for all cancers combined and specific cancers across both genders and age groups, with the exception of liver cancer in people aged 55 and up.
'In 2021, for [the 55-plus age group], liver cancer had the highest alcohol-associated proportional [mortality rate] in males (38.5 percent), followed by nasopharyngeal cancer (31.8 percent), while in females, nasopharyngeal (18.9 percent) and oro/hypopharyngeal cancers (18.4 percent) ranked highest. In 20-54 age, lip-oral cavity cancer had the highest alcohol-associated proportional [rates] for both genders,' they noted.
The researchers identified Washington, D.C., as the area with the highest rates of alcohol-associated cancer. Utah had the lowest.
An increasing number of women have become heavy drinkers, although alcohol abuse still kills more men than women. While drinking rates dropped from the 1970s through the 1990s, they also rose during the Covid pandemic. So did alcohol-related deaths.
'This is death as opposed to getting a disease. We can treat a lot of cancers, and we're getting better at that, but this is really driving home the point that people are dying from cancer due to alcohol,' said Jane Figueiredo, a professor of medicine at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, who was not involved with the research told NBC News.
The research, which has not yet been published in a peer-reviewed journal, comes after former U.S. Surgeon General Dr. Vivek Murthy issued a call for cancer risk warnings to be included on alcoholic beverages.
"Alcohol is a well-established, preventable cause of cancer responsible for about 100,000 cases of cancer and 20,000 cancer deaths annually in the United States - greater than the 13,500 alcohol-associated traffic crash fatalities per year in the U.S. - yet the majority of Americans are unaware of this risk," he said in a news release earlier in the year.
The researchers cited this warning in their report, noting that alcohol consumption is known to be a significant risk factor for cancer.
The International Agency on Cancer Research, a branch of the World Health Organization, classified alcohol as a carcinogen in 1987, and the organization says there's no safe amount of alcohol consumption.
The Centers for Disease Control and Prevention had previously said that approximately 20,000 adults in the U.S. die from alcohol-associated cancers each year. The agency noted that most of the deaths may have been avoided if all adults had followed the recommended limits on alcohol use.
The authors of the recent research said their findings indicate the need for enhanced prevention.
'Our findings highlight the critical need for targeted prevention efforts, public health policies, and increased awareness to address the rising impact of alcohol consumption on cancer-related mortality across different demographic groups and regions,' they said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Omada Health IPO signals healthier market, avoids 'down-round' trend
Omada Health IPO signals healthier market, avoids 'down-round' trend

Yahoo

time4 hours ago

  • Yahoo

Omada Health IPO signals healthier market, avoids 'down-round' trend

The IPO market is starting to feel healthier. Omada Health, a 14-year-old company providing virtual care for chronic conditions like diabetes and hypertension between office visits, closed its first trading day on Friday at $23 a share, a 21% jump from the IPO price of $19. The IPO valued the company just above $1 billion (excluding employee options), a figure that's nearly identical to Omada's last private valuation of $1 billion set in its previous VC round. The debut is one of the first among recent IPOs that was not a so-called down-round. Many of the latest public listings, including Hinge, ServiceTitan, and Reddit, priced below their private market highs, though have faired well as public companies. For founder and CEO Sean Duffy, the successful public offering validates his decision to start a company that he believed the market desperately needed. In 2011, he dropped out of Harvard Medical School after realizing that chronic illness patients required more continuous support than the existing healthcare system delivered. Before the offering, he owned 4.1% of the company, according to Omada's offering document. Other significant shareholders included Revelation Partners (10.9%), US Venture Partners (9.9%), Andreessen Horowitz (9.6%), and FMR (9.3%). Duffy told TechCrunch that over his 14-year journey as a founder, he had many harrowing moments. "I didn't think our series A was going to come together because we were working on this commercial deal that didn't materialize, and that spooked one investor," he said. "As a young business, something tries to kill you every month," he continued. "And then as the business grows, it turns into like every quarter or six months, year, two years." One of the recent challenges for many digital health businesses is navigating the "collapse" of the market post-COVID boom. Omada steered through the turbulent times by seeking new, rising markets. It recently expanded its offerings to include diet management support for GLP-1 patients.

Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction

Yahoo

time4 hours ago

  • Yahoo

Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction

Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store